
Auteur A. J. KROTULSKI
|
Documents disponibles écrits par cet auteur (4)

E. BARENHOLTZ ; A. J. KROTULSKI ; P. MORRIS ; N. D. FITZGERALD ; A. LE ; D. M. PAPSUN ; B. K. LOGAN ; W. E. HAHN ; B. A. GOLDBERGER ; L. B. COTTLER ; J. J. PALAMAR | 2021
Dans International Journal of Drug Policy (Vol.98, December 2021) Article : PériodiqueBackground: Novel psychoactive substances (NPS) present continuous and growing challenges for the scientific, medical, and interventional communities as emerging substances on recreational drug markets change national and international drug land[...]
J. S. LOVE ; M. LEVINE ; K. ALDY ; J. BRENT ; A. J. KROTULSKI ; B. K. LOGAN ; C. VARGAS-TORRES ; S. E. WALTON ; A. AMADUCCI ; D. CALELLO ; R. HENDRICKSON ; A. HUGHES ; A. KURT ; B. JUDGE ; A. PIZON ; E. SCHWARZ ; J. SHULMAN ; T. WIEGAN ; P. WAX ; A. F. MANINI | 2023
Dans Clinical Toxicology (Vol.61, n°3, March 2023) Article : PériodiqueIntroduction: Illicit opioids, consisting largely of fentanyl, novel synthetic opioids, and adulterants, are the primary cause of drug overdose fatality in the United States. Xylazine, an alpha-2 adrenergic agonist and veterinary tranquilizer, i[...]
B. K. LOGAN ; A. L. A. MOHR ; M. FRISCIA ; A. J. KROTULSKI ; D. M. PAPSUN ; S. L. KACINKO ; J. D. ROPERO-MILLER ; M. A. HUESTIS | 2017
Dans Journal of Analytical Toxicology (Vol.41, n°7, September 2017) Article : PériodiqueNovel psychoactive substances (NPS) represent significant analytical and interpretive challenges to forensic and clinical toxicologists. Timely access to case reports and reports of adverse incidents of impairment or toxicity is imperative to cl[...]
A. J. KROTULSKI ; A. CANNAERT ; C. STOVE ; B. K. LOGAN | 2021
Dans Drug Testing and Analysis (Vol.13, n°2, February 2021) Article : PériodiqueA new class of synthetic cannabinoids has emerged as new psychoactive substances (NPS). Similar in structure to JWH-022, these substances contain alkene modifications to the tail region of the synthetic cannabinoid core structure, and nomenclatu[...]